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G amma;-glutamyl transferase (GGT) has been regarded as a biomarker of hepatobiliary disease and alcohol consumption/abuse. 1 However, GGT is elaborated by extrahepatic tissues including the kidney, epididymis, fibroblasts, lymphocytes, and lung. [2] [3] [4] Accumulating experimental evidence suggests an important role for GGT in extracellular catabolism of glutathione, the principal thiol antioxidant in humans. GGT enhances the availability of cysteine to promote intracellular glutathione (GSH) resynthesis, thereby counteracting oxidant stress. 2, 5, 6 GGT adsorbs onto circulating low-density lipoprotein cholesterol (LDL) and can catalyze its oxidation. 7 It is expressed in the atheromatous core of coronary plaques, where it colocalizes with oxidized LDL and foam cells. 8 GGT may also be proinflammatory, because it mediates interconversion of the glutathione-containing inflammatory mediator leukotriene C4 into leukotriene D4. 9 Parallel evidence from epidemiological studies suggest that higher serum GGT is associated with development of cardio-vascular disease (CVD) risk factors, including diabetes, hypertension, dyslipidemia, 10 -13 and the metabolic syndrome. 10 GGT levels correlate positively with novel cardiovascular risk factors such as C-reactive protein (CRP), fibrinogen, F2-isoprostanes, 14 and inversely with antioxidant levels. 15 Prior studies associated increased GGT with mortality attributable to ischemic heart and cerebrovascular disease, 16 -18 but have not addressed whether serum GGT reflects greater burden of CVD risk factors 12, 13, 19 or whether GGT has incremental prognostic utility beyond these risk factors. 20, 21 Although prior studies have had unique strengths, they did not adjust for established cardiovascular risk factors or CRP 16, [22] [23] [24] and had limited end point selection. 24 We examined the cross-sectional clinical correlates of serum GGT and evaluated, longitudinally, whether higher levels predicted future CVD events and mortality in the Framingham Heart Study. We hypothesized that increasing serum GGT would be associated with elevated risk of new-onset metabolic syndrome, incident CVD, and all-cause mortality after accounting for established and novel cardiovascular risk factors. We postulated that GGT would predict CVD risk even after adjusting for vascular risk factors as time-dependent variables during follow-up.
Methods

Study Participants
The Framingham Offspring Study began in 1971 with the enrollment of 5124 offspring of the original cohort participants (and their spouses). 25 The second examination cycle (1978 -1982) , was attended by 3853 offspring participants (1864 men, 1989 women). Of these, 402 were excluded for the following reasons: missing GGT data (nϭ234, 6%), prevalent CVD (nϭ151, 4%), and missing covariate data (nϭ17, 0.4%). Prior CVD was defined as presence of coronary heart disease (myocardial infarction, coronary insufficiency, angina pectoris), peripheral vascular disease (intermittent claudication), cerebrovascular disease (stroke or transient ischemic attack), or heart failure. 26 At each quadrennial Heart Study examination, participants underwent standardized measurements of blood pressure (BP), anthropometry, medical history, physical examination, and laboratory assessment of cardiovascular risk factors. All participants provided written informed consent and the study protocol was approved by the Institutional Review Board of the Boston Medical Center.
Measurements and Definitions
Systolic and diastolic BP were the average of two physician-obtained measurements performed after participants had rested at least 5 minutes in a sitting position, using a mercury sphygmomanometer. Hypertension was defined as a systolic BP Ն140 mm Hg or a diastolic BP Ն90 mm Hg, or the use of antihypertensive medication. Current smoking was self-reported and was defined as having smoked cigarettes regularly within the prior year. Alcohol consumption was defined based on self-reported average weekly intake. Serum triglycerides, total and HDL cholesterol, and blood glucose were measured after an overnight fast. Diabetes was defined by fasting blood glucose Ն126 mg/dL or the use of oral hypoglycemic agents or insulin.
Participants underwent phlebotomy after an overnight fast (between 10 to 12 hours), typically between 7.30 AM and 9 AM. Blood was immediately centrifuged, and plasma and serum specimens were stored at Ϫ20°C until assayed. Uniform measurement of GGT activity in serum was performed using spectrophotometry by detecting the liberation of p-nitroaniline at 405 nm, resulting from the reaction of ␥-glutamyl-p-nitroanilide ϩ glycylglycine (Quest Diagnostics [MedPath]). 27 High-sensitivity C-reactive protein (CRP) was measured with a Dade Behring BN100 nephelometer from specimens also obtained at the second offspring examination cycle. The average intra-assay coefficient of variation for CRP was 3.8%.
Cross-Sectional Correlates of GGT
We evaluated the association of baseline serum GGT with CVD risk factors and clinical covariates including age, sex, systolic and diastolic BP, hypertension, LDL and HDL cholesterol, serum triglycerides, fasting blood glucose, diabetes, body mass index (BMI), smoking status, and alcohol consumption. We compared serum GGT levels according to presence of metabolic syndrome at baseline, using modified National Cholesterol Education Program (NCEP) criteria, which required at least three of: (1) elevated triglycerides, Ն150 mg/dL; (2) HDL cholesterol Ͻ40 mg/dL [men] or Ͻ50 mg/dL [women]; (3) BP Ն130 mm Hg systolic, Ն85 mm Hg diastolic, or on antihypertensive therapy; (4) fasting blood glucose Ն100 mg/dL; and (5) BMI Ն30 kg/m 2 . 28 We substituted BMI for increased waist circumference because measurements of waist were not obtained at baseline examination.
Prospective Follow-Up for Incident Events
Participants were followed prospectively for development of metabolic syndrome, incident CVD (fatal or non-fatal coronary heart disease, peripheral vascular disease, cerebrovascular disease, or heart failure), and death over a maximum follow-up duration of 20 years. All CVD events and deaths were systematically reviewed by a three-investigator panel after evaluating all available office and hospitalization records, laboratory test results, death certificates, and autopsy reports.
Statistical Analysis
Cross-Sectional Correlates of GGT
The distribution of GGT values was right-skewed, therefore a ln-transformation was applied. To account for an upward shift in log-GGT in men relative to women, we standardized the distribution (meanϭ0, SDϭ1) within each sex. The distributions of serum triglyceride and alcohol consumption were skewed, and were also log-transformed. Cross-sectional correlates of GGT were identified using sex-pooled multiple linear regression analysis. Each potential correlate was examined separately in age/sex-adjusted models. Variables that were statistically significant at ␣ϭ0.05 in these models were evaluated in multivariable analysis with forward stepwise selection; covariates significant at ␣ϭ0.15 were retained.
Longitudinal Analysis of GGT and Clinical Events
We used Cox proportional hazards regression to examine the association of baseline GGT with: (1) metabolic syndrome, (2) incident CVD, and (3) all-cause mortality, over 20 year follow-up. We constructed Cox models for pooled sexes because formal tests of interaction (sexϫlog-GGT) were not statistically significant for any outcome. Initially, we determined the risk associated with a onestandard deviation increment in standardized log-transformed GGT. Cutpoints for sex-specific quartiles were defined based on the GGT distribution of all participants at baseline (prior to exclusions). We compared the risk of events in quartiles 2 to 4 relative to the lowest quartile, and also tested for linear trend across quartiles.
For new-onset metabolic syndrome, the primary analysis examined events over the entire study duration (20 years), after excluding participants with metabolic syndrome at baseline. We also examined the risk of metabolic syndrome according to GGT during short-term follow-up (8-years). New-onset metabolic syndrome was defined by presence of the modified NCEP diagnostic criteria at any subsequent quadriennial examination. 29 Because ascertainment of metabolic syndrome required attendance at Heart Study examinations (wheras CVD or death are ascertained irrespective of Heart Study visits), we terminated follow-up at the last examination date if Ͼ2 consecutive examination cycles were unattended. Cox models were adjusted initially for factors unrelated to the metabolic syndrome definition: age, sex, alcohol consumption, and log-CRP. In secondary analysis, we evaluated whether GGT predicted new-onset metabolic syndrome after additional adjustment for BMI, fasting blood glucose, systolic and diastolic BP, serum triglycerides, and smoking.
For analyses relating GGT to risk of incident CVD and death, we constructed age/sex-adjusted cumulative incidence curves to illustrate risk across GGT quartiles. Cox models estimating risk of incident CVD and mortality were adjusted for age, sex, BMI, diabetes, systolic BP, antihypertensive treatment, total/HDL cholesterol ratio, current smoking, and alcohol consumption at baseline. Additionally, we adjusted for serum creatinine concentration and education level (postsecondary versus non) as an indicator of socioeconomic status in CVD models. Furthermore, we adjusted for aspartate and alanine aminotransferases (AST, ALT), because reports have linked these enzymes to CVD and metabolic syndrome. 30, 31 Additionally, we adjusted for: (1) baseline CRP; (2) baseline CRP and all other covariates modeled as time-dependent variables (updated at each subsequent quadrennial Framingham examination attended). We examined the discrimination of models that included clinical covariates and log-GGT with and without log-CRP to determine the incremental value of the latter after accounting for GGT, using the c-statistic. In Cox models, we confirmed that the assumption of proportionality of hazards was met. 32 Statistical analyses were performed using SAS version 8.2 (Cary, NC) and a two-sided probability value Յ0.05 was considered statistically significant.
Results
Cross-Sectional Correlates of GGT
Participants in higher GGT quartiles were older, had higher BMI, and were more likely to have hypertension, and elevated lipids, fasting blood glucose, and CRP (Table 1; PϽ0.001 for quartile trend). In the highest quartile, 81.4% of men and 86.9% of women had GGT values within the normal reference range (eg, men Յ50 U/, women Յ40 U/). Crosssectionally, presence of the metabolic syndrome was associated with higher GGT in men (24.9Ϯ15.3 versus 18.9Ϯ14.7 U/; PϽ0.001) and women (19.8Ϯ15.0 versus 11.4Ϯ9.2 U/; PϽ0.001). In stepwise multiple regression models (see the supplemental materials, available online at http://atvb.ahajournals.org), log-GGT was positively associated with age (Pϭ0.009), male sex, smoking, BMI, LDL cholesterol, serum triglycerides, alcohol consumption, diastolic BP, hypertension treatment (PՅ0.001 for all), and fasting blood glucose (Pϭ0.004). The above factors explained 33% of the interindividual variability in GGT; sex, serum triglycerides, and alcohol consumption were principal correlates explaining a large degree of variation. There was weak positive correlation of log-GGT with log-CRP (Pearson's rϭ0.27, PϽ0.001), which was of consistent magnitude in men (rϭ0.26) and women (rϭ0.27).
Serum GGT and Incidence of the Metabolic Syndrome
On follow-up, 419 participants (16%, 192 women) developed metabolic syndrome at 8 years, and 968 individuals (37%, 479 women) developed metabolic syndrome over a 20-year period. In multivariable Cox models adjusted for age, sex, alcohol consumption, and CRP, higher GGT was associated with greater risk of developing the metabolic syndrome with a 134% (8-year) to 76% (20-year) increased risk in the top quartile relative to the lowest ( Table 2 ). In models evaluating (16) 118 (14) 119 (15) 123 (17) 127 (17) Diastolic BP, mm Hg (SD) † 78 (10) 75 (8) 76 (10) 79 (10) 81 (9) Hypertension, n (%) † 602 (17) 78 (10) 124 (13) 165 (21) 235 (26) Treated hypertension, n (%) † 327 (9) 
Serum GGT and CVD and Mortality Risk
A total of 65 900 person-years of observation was available in 3451 participants for incident CVD and death. On follow-up (mean 19.1Ϯ3.0 years), 535 participants (15.5%; 173 women) experienced incident CVD, and 362 individuals died (10.5%; 131 women). Age/sex-adjusted cumulative incidence of CVD and death (Figures 1 and 2) displayed an increasing gradient of risk across GGT quartiles (log-rank PϽ0.001 for both outcomes).
In multivariable models adjusting for established risk factors and CRP, log-GGT was positively related to CVD incidence and a graded increase in CVD risk was observed across GGT quartiles ( Table 3 ). The association of GGT with CVD was maintained in models incorporating CVD risk factors as time-varying covariates ( Table 3) . A 1-SD increment in log-CRP was associated with a 1.20-fold (95%CI; 1.07 to 1.33, PϽ0.001) risk of incident CVD. After additionally adjusting for serum creatinine concentration and education level, a 1-SD increment in GGT was still associated with a 15% increase in CVD (HR 1.15, 95%CI; 1.05 to 1.27, Pϭ0.004). Those in the highest GGT quartile had a 1.66-fold risk (95%CI; 1.22 to 2.26, Pϭ0.001), and a significant trend was present across quartiles (PϽ0.001).
In multivariable analyses of mortality, the risk increased across GGT quartiles, remaining robust even after adjustment for log-CRP, and risk factors modeled as time-varying covariates ( Table 4 ). Accounting for log-CRP and all other risk factors as time-varying covariates, a 1-SD increment in log-GGT was associated with a 26% increased risk of death. A 1-SD increment in log-CRP was associated with a 1.31fold (95%CI; 1.16 to 1.47, PϽ0.001) risk in the latter models. The associations of GGT with incident CVD and death were maintained after adjustment for serum AST and ALT (data not shown).
Adjusting for clinical covariates (eg, age, sex, BMI, diabetes, systolic BP, total/HDL cholesterol ratio, current smoking, alcohol consumption) and log-GGT, the c-statistic for CVD risk was 0.785 (95%CI; 0.766 to 0.804). When log-CRP was added, the c-statistic increased minimally to 0.786 1 . Age/sex-adjusted cumulative incidence of CVD by GGT quartile. Numbers at risk are not the same in each quartile because cut points were determined on all participants with available GGT data (before exclusions).
(95%CI; 0.767 to 0.805). Similarly, the model for mortality including clinical covariates and log-GGT had a c-statistic of 0.799 (95%CI; 0.778 to 0.821), and addition of log-CRP increased it minimally to 0.802 (95%CI; 0.780 to 0.823).
There was no significant interaction between GGT and CRP for CVD or mortality prediction.
Discussion
Principal Findings
The principal findings of our investigations are three-fold. First, serum GGT levels were related cross-sectionally to CVD risk factors, notably increased age, male sex, dyslipidemia, BMI, glycemia, BP, and smoking. Second, higher serum GGT was associated prospectively with increased incidence of the metabolic syndrome, above and beyond conventional risk factors including CRP. Third, serum GGT was positively associated with incident CVD and death, after accounting for CRP and hepatic enzymes. Because GGT was associated with the metabolic syndrome prospectively, we adjusted for established CVD risk factors as time-varying covariates, and the association of GGT with CVD and mortality remained, suggesting that GGT risk occurs by mechanisms other than promotion/development of known risk factors. Overall, our data suggest that serum GGT predicts development of the CVD risk factor cluster that constitutes the metabolic syndrome, CVD events, and mortality.
Comparison With Prior Research
Prior studies suggested that higher GGT levels predicted all-cause mortality in patients with myocardial infarction or coronary artery disease, 20, 21 and in middle-aged individuals free of preexisting coronary disease. 16, 24 Prior studies were limited by use of death certificate diagnoses of coronary heart disease, and none addressed whether GGT predicted vascular risk via promotion of established risk factors. 16 Our observations relating GGT to fatal and nonfatal incident CVD events in a community-based sample complement prior studies reporting that higher GGT is associated with cardiovascular death. 33 We expand on prior work by demonstrating that GGT is associated with incident CVD even after accounting for baseline CRP, and risk factors modeled as time-varying covariates. Although GGT was weakly correlated with CRP in our sample and in prior studies, 34 CRP did not abrogate the predictive value of GGT for clinical events. First, adjustment for CRP did not attenuate the association of GGT with CVD or mortality. Second, there was minimal additional effect on model discrimination when CRP was added to a model comprised of clinical covariates and GGT. Finally, there was no statistical interaction between GGT and CRP. Our findings suggest that GGT, a routinely-available metabolic marker and indicator of oxidative stress, is a significant predictor of CVD and mortality events independent of CRP. Our findings suggest that GGT will be an important component of future biomarker and multimarker approaches to cardiovascular risk evaluation.
Potential Mechanisms of GGT Effect
Mechanisms that explain the contribution of GGT to CVD and mortality have not been fully elucidated. GGT is associated with hepatic steatosis 35 and insulin resistance, 22, 23 and is a predictor of incident hypertension 36 and diabetes. 13, 37 Although we observed that the relations of GGT to cardiovascular events and death remained robust after accounting for fasting glucose and components of the metabolic syndrome, it is conceivable that such adjustment incompletely accounts for hepatic insulin resistance and/or steatosis. 38 The activity of ectoenzymatic GGT may also modulate the redox status of protein thiols at the cell surface, leading to production of reactive oxygen species and membrane-permeable hydrogen peroxide. 39 As noted previously, GGT contributes to oxidative stress pathways in several organ systems, localizes to atheromatous plaques containing oxidized LDL, and is proinflammatory, further implicating this protein in atherogenesis. 34, 40, 41 
Strengths and Limitations
The strengths of our investigation are its prospective design, consistent definition and validation of CVD events, complete longitudinal ascertainment of deaths, accounting for risk factors as time-varying covariates, and adjustment for CRP. The biological plausibility that GGT mediates vascular risk is reflected by the strength of the associations, temporal relations between baseline GGT and future vascular risk, and consistency of the results across several analyses. Several limitations of our approach merit comment. Establishing that GGT is a "risk factor" for CVD would require additional mechanistic studies that further assess systemic oxidative stress, and evaluate hepatic steatosis and insulin resistance. We did not obtain repeated GGT or CRP measurements but used baseline values, which is a potential limitation because changes could occur over time. 23 Also, we did not extend this study to other emerging biomarkers of vascular risk. Nonetheless, GGT assays are widely available analytes which are routinely measurable in clinical laboratories. Lastly, the overwhelming majority of our sample was white, limiting the generalizability to other ethnicities.
Conclusions
In our community-based sample, higher GGT levels predicted CVD, mortality, and development of the metabolic syndrome. The association of GGT with adverse cardiovascular outcomes and death was robust after adjustment for traditional cardiac risk factors and CRP. Our study suggests that further investigation of GGT will provide insights into the pathogenesis of CVD and better define the clinical utility of this marker. 
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